Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Tesla Raises Cybertruck Prices by $5,000 in US 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Nvidia Options Price in $280 Billion Earnings Swing 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Add as a preferred source on Google
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for
May 10, 2018, 4:30 p.m. ET
CORALVILLE, Iowa, May 01, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, May 10, 2018, at 4:30 p.m. ET, to discuss its corporate and financial results for the first quarter 2018.
Conference Call Information:
Interested participants and investors may access the conference call by dialing either:
- (866) 395-2480 (U.S.)
- (678) 509-7538 (international)
- Conference ID: 3649247
An audio webcast with slide presentation will be accessible via the Investor Relations section of the KemPharm website http://investors.kempharm.com/. An archive of the webcast and presentation will remain available for 90 days beginning at approximately 5:30 p.m. ET, on May 10, 2018.
About KemPharm
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LATTM (Ligand Activated Therapy) platform technology. KemPharm utilizes its proprietary LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of ADHD, pain and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release/effect profiles for the treatment of ADHD. In addition, the company has received FDA approval for APADAZ™, an immediate-release combination product candidate of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company is also advancing KP201/IR, an acetaminophen-free immediate-release formulation of the company’s benzhydrocodone prodrug candidate. Both APADAZ and KP201/IR are intended for the treatment of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.
| Investor Contacts: | Media Contact: |
| Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] | Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected] |
